Last updated on July 2018

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors


Brief description of study

This study is an open-label, multicenter, phase 1 study of SyB C-0501 by continuous daily oral administration in patients with advanced solid tumors, who have previously received anticancer therapy and consists of two parts. Part 1 is a dose escalation study to evaluate tolerability of SyB C-0501 in the patients, and to find the maximum tolerated dose (MTD), recommended dose (RD) and optimum dosing schedule. Part 2 is being done to evaluate safety and anti-tumor activity of SyB C-0501 preliminarily at RD, and to assess its target cancer exploratory.

Clinical Study Identifier: NCT03604679

Contact Investigators or Research Sites near you

Start Over

Shiho Takeda

Research Site
Osakasayama, Japan
  Connect »